487 related items for PubMed ID: 18204133
1. Efficacy and safety of once or twice daily inhalation of extrafine HFA beclomethasone dipropionate in patients with mild to moderate asthma.
Gillissen A, Richter A, Oster H, Criée CP.
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):233-41. PubMed ID: 18204133
[Abstract] [Full Text] [Related]
2. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol.
Fireman P, Prenner BM, Vincken W, Demedts M, Mol SJ, Cohen RM.
Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808
[Abstract] [Full Text] [Related]
3. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose.
Davies RJ, Stampone P, O'Connor BJ.
Respir Med; 1998 Jun; 92 Suppl A():23-31. PubMed ID: 9850360
[Abstract] [Full Text] [Related]
4. Efficacy and safety of beclomethasone dipropionate extrafine aerosol in childhood asthma: a 12-week, randomized, double-blind, placebo-controlled study.
Nayak A, Lanier R, Weinstein S, Stampone P, Welch M.
Chest; 2002 Dec; 122(6):1956-65. PubMed ID: 12475833
[Abstract] [Full Text] [Related]
5. Health-related quality of life in moderate asthma: 400 microg hydrofluoroalkane beclomethasone dipropionate vs 800 microg chlorofluorocarbon beclomethasone dipropionate. The Study Group.
Juniper EF, Buist AS.
Chest; 1999 Nov; 116(5):1297-303. PubMed ID: 10559091
[Abstract] [Full Text] [Related]
6. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma.
Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J.
Chest; 1999 Feb; 115(2):343-51. PubMed ID: 10027430
[Abstract] [Full Text] [Related]
7. Effectiveness of low doses (50 and 100 microg b.i.d) of beclomethasone dipropionate delivered as a CFC-free extrafine aerosol in adults with mild to moderate asthma. Study Group.
Hampel F, Lisberg E, Guérin JC.
J Asthma; 2000 Aug; 37(5):389-98. PubMed ID: 10983616
[Abstract] [Full Text] [Related]
8. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant.
Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, Donnell D, Hannon S, Colice GL.
J Allergy Clin Immunol; 1999 Dec; 104(6):1215-22. PubMed ID: 10589004
[Abstract] [Full Text] [Related]
9. Safety and efficacy of HFA-134a beclomethasone dipropionate extra-fine aerosol over six months.
Boulet LP, Cartier A, Ernst P, Larivée P, Laviolette M.
Can Respir J; 2004 Mar; 11(2):123-30. PubMed ID: 15045043
[Abstract] [Full Text] [Related]
10. Clinical efficacy of short-term treatment with extra-fine HFA beclomethasone dipropionate in patients with post-infectious persistent cough.
Gillissen A, Richter A, Oster H.
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):223-32. PubMed ID: 18204132
[Abstract] [Full Text] [Related]
11. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.
Chrousos GP, Ghaly L, Shedden A, Iezzoni DG, Harris AG.
Chest; 2005 Jul; 128(1):70-7. PubMed ID: 16002918
[Abstract] [Full Text] [Related]
12. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children.
Pedersen S, Warner J, Wahn U, Staab D, Le Bourgeois M, Van Essen-Zandvliet E, Arora S, Szefler SJ, Pediatric Study Group.
Pediatrics; 2002 Jun; 109(6):e92. PubMed ID: 12042586
[Abstract] [Full Text] [Related]
13. Efficacy of chlorofluorocarbon-free beclomethasone dipropionate 400 micrograms day-1 delivered as an extrafine aerosol in adults with moderate asthma.
Matthys H, Nowak D, Hader S, Kunkel G.
Respir Med; 1998 Jun; 92 Suppl A():17-22. PubMed ID: 9850359
[Abstract] [Full Text] [Related]
14. A new HFA-134a propellant in the administration of inhaled BDP via the Jet spacer: controlled clinical trial vs the conventional CFC.
Vondra V, Sladek K, Kotasová J, Terl M, Rossetti A, Cantini L.
Respir Med; 2002 Oct; 96(10):784-9. PubMed ID: 12412977
[Abstract] [Full Text] [Related]
15. Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma.
Micheletto C, Guerriero M, Tognella S, Dal Negro RW.
Respir Med; 2005 Jul; 99(7):850-5. PubMed ID: 15939246
[Abstract] [Full Text] [Related]
16. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma.
Aubier M, Wettenger R, Gans SJ.
Respir Med; 2001 Mar; 95(3):212-20. PubMed ID: 11266239
[Abstract] [Full Text] [Related]
17. Improved control of asthma symptoms with a reduced dose of HFA-BDP extrafine aerosol: an open-label, randomised study.
Ederle K, Multicentre Study Group.
Eur Rev Med Pharmacol Sci; 2003 Mar; 7(2):45-55. PubMed ID: 12911119
[Abstract] [Full Text] [Related]
18. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma.
Reichel W, Dahl R, Ringdal N, Zetterstrom O, van den Elshout FJ, Laitinen LA.
Int J Clin Pract; 2001 Mar; 55(2):100-6. PubMed ID: 11321849
[Abstract] [Full Text] [Related]
19. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant.
Woodcock A, Williams A, Batty L, Masterson C, Rossetti A, Cantini L.
J Aerosol Med; 2002 Mar; 15(4):407-14. PubMed ID: 12581507
[Abstract] [Full Text] [Related]
20. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
Fowler SJ, Currie GP, Lipworth BJ.
J Allergy Clin Immunol; 2002 Jun; 109(6):929-35. PubMed ID: 12063520
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]